Who is it for?
Digistain® works biologically downstream using a proprietary method to measure markers at the protein level to deliver a robust and personalised risk score for cancer therapy guidance
Designed for invasive breast cancer patients who are:
Stage 1 - 2
HER2-
ER+
up to 3 positive lymph nodes
Digistain is suitable for women with Stage 1 to Stage 2 invasive breast cancer that is hormone receptor-positive, HER2- and with no more than three affected lymph nodes.
